Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) Invested Capital: 2017-2025

Historic Invested Capital for Autolus Therapeutics (AUTL) over the last 8 years, with Sep 2025 value amounting to $265.5 million.

  • Autolus Therapeutics' Invested Capital fell 44.35% to $265.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $265.5 million, marking a year-over-year decrease of 44.35%. This contributed to the annual value of $427.3 million for FY2024, which is 283.34% up from last year.
  • As of Q3 2025, Autolus Therapeutics' Invested Capital stood at $265.5 million, which was down 23.38% from $346.5 million recorded in Q2 2025.
  • Autolus Therapeutics' 5-year Invested Capital high stood at $582.0 million for Q1 2024, and its period low was $111.5 million during Q4 2023.
  • In the last 3 years, Autolus Therapeutics' Invested Capital had a median value of $346.5 million in 2025 and averaged $344.1 million.
  • Its Invested Capital has fluctuated over the past 5 years, first crashed by 62.68% in 2023, then surged by 283.34% in 2024.
  • Quarterly analysis of 5 years shows Autolus Therapeutics' Invested Capital stood at $313.3 million in 2021, then fell by 4.67% to $298.7 million in 2022, then plummeted by 62.68% to $111.5 million in 2023, then surged by 283.34% to $427.3 million in 2024, then crashed by 44.35% to $265.5 million in 2025.
  • Its last three reported values are $265.5 million in Q3 2025, $346.5 million for Q2 2025, and $371.1 million during Q1 2025.